Overview

Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 2 study is to assess the pharmacokinetics (PK) and safety of RLYB212 in HPA-1b/b pregnant women at higher risk for HPA-1a alloimmunization and FNAIT.
Phase:
PHASE2
Details
Lead Sponsor:
Rallybio